Impact of the serum bone-specific alkaline phosphatase level at the initiation of hemodialysis therapy for end-stage renal disease on cardiovascular events
IJC Metabolic & Endocrine · 2014
DOI: 10.1016/j.ijcme.2014.06.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift IJC Metabolic & Endocrine, 2014. Verfasst von Noritoshi Fukushima und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Abstract (Originalsprache)
Patients with end-stage renal disease (ESRD) have high rates of hospitalization for cardiovascular (CV) events and short-term mortality after the initiation of hemodialysis (HD) therapy. To improve outcomes, it is important to identify predictive laboratory markers. We investigated whether the serum bone-specific alkaline phosphatase (BAP) level at the initiation of HD therapy for ESRD was associated with adverse events. This was a retrospective cohort study of 47 ESRD outpatients who were referred to our clinic for HD. The serum BAP level was measured within 1 month after the initiation of HD. Patients were divided into high-BAP and low-BAP groups according to the median serum BAP level (24.6 U/L). The impact of the serum BAP level on CV events (coronary artery disease, peripheral arterial disease, cerebrovascular disease, other CV events including aortic dissection, and mortality) was investigated. During a median follow-up period of 72 months, CV events occurred in 14 patients (29.8%). Kaplan–Meier analysis showed that the disease-free and overall survival rates were lower in the high-BAP group than in the low-BAP group (p = 0.003 and p = 0.037, respectively, log-rank test). After adjustment for age, sex, and other confounding factors, Cox proportional hazards analysis found that the high-BAP group had a 5.9-fold higher rate of CV events than the low-BAP group (hazard ratio: 5.89; 95% confidence interval: 1.184–29.309; p = 0.030). The serum BAP level at the initiation of HD therapy for ESRD is a useful non-invasive biomarker for predicting CV events.
Zitieren
APA
Fukushima, N., Suzuki, A., Fukushima, K., Tanaka, Y., Sato, Y., Shiga, T., Nitta, K., & Hagiwara, N. (2014). Impact of the serum bone-specific alkaline phosphatase level at the initiation of hemodialysis therapy for end-stage renal disease on cardiovascular events. IJC Metabolic & Endocrine. https://doi.org/10.1016/j.ijcme.2014.06.002
Vancouver
Fukushima N, Suzuki A, Fukushima K, Tanaka Y, Sato Y, Shiga T, et al. Impact of the serum bone-specific alkaline phosphatase level at the initiation of hemodialysis therapy for end-stage renal disease on cardiovascular events. IJC Metabolic & Endocrine. 2014. doi:10.1016/j.ijcme.2014.06.002
BibTeX
@article{Fukushima2014,
author = {Fukushima, Noritoshi and Suzuki, Atsushi and Fukushima, Keiko and Tanaka, Yoshiko and Sato, Yasuto and Shiga, Tsuyoshi and Nitta, Kosaku and Hagiwara, Nobuhisa},
title = {Impact of the serum bone-specific alkaline phosphatase level at the initiation of hemodialysis therapy for end-stage renal disease on cardiovascular events},
journal = {IJC Metabolic & Endocrine},
year = {2014},
doi = {10.1016/j.ijcme.2014.06.002}
}
EUVIMED